These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25733062)

  • 1. Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down.
    Trimarchi H
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(1):2-14. PubMed ID: 25733062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
    Herrera M; Söderberg M; Sabirsh A; Valastro B; Mölne J; Santamaria B; Valverde AM; Guionaud S; Heasman S; Bigley A; Jermutus L; Rondinone C; Coghlan M; Baker D; Quinn CM
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F748-F759. PubMed ID: 27440778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in B7-1-positive proteinuric kidney disease.
    Yu CC; Fornoni A; Weins A; Hakroush S; Maiguel D; Sageshima J; Chen L; Ciancio G; Faridi MH; Behr D; Campbell KN; Chang JM; Chen HC; Oh J; Faul C; Arnaout MA; Fiorina P; Gupta V; Greka A; Burke GW; Mundel P
    N Engl J Med; 2013 Dec; 369(25):2416-23. PubMed ID: 24206430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
    Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
    Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of CTLA-4 in the regulation and initiation of T-cell responses.
    Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
    Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
    [No Abstract]   [Full Text] [Related]  

  • 7. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4Ig: uses and future directions.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):132-42. PubMed ID: 19519590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complexities of T-cell co-stimulation: CD28 and beyond.
    Sperling AI; Bluestone JA
    Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
    [No Abstract]   [Full Text] [Related]  

  • 10. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
    Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
    Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
    Linsley PS; Greenbaum CJ; Speake C; Long SA; Dufort MJ
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocentric view of glomerular proteinuria: Focused on cytoskeletal changes and toward promising targeted therapies and challenges.
    Kuo MC; Liang PI; Chang JM
    Kaohsiung J Med Sci; 2021 Jul; 37(7):539-546. PubMed ID: 33942997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
    Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
    Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.
    Bassi R; Fornoni A; Doria A; Fiorina P
    Diabetologia; 2016 Jan; 59(1):21-29. PubMed ID: 26409459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
    Boussiotis VA; Freeman GJ; Gribben JG; Daley J; Gray G; Nadler LM
    Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11059-63. PubMed ID: 7504293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
    Krummel MF; Allison JP
    J Exp Med; 1995 Aug; 182(2):459-65. PubMed ID: 7543139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
    Linsley PS; Ledbetter J; Peach R; Bajorath J
    Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
    [No Abstract]   [Full Text] [Related]  

  • 20. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
    Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
    Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.